Research and Development

Research and Development

We constantly invest in research and development by expanding its portfolio and offering more affordable products to its customers.

Listen to the text Stop the audio

The Research and Development (R&D) area is starting to reap the fruits of its well-structured long-term expansion plan, with a focus on innovative drugs. The plan has included the opening of Eurolab in 2020, one of the largest and most modern pharmaceutical research centers in Latin America, and the hiring of qualified scientists and professionals for the projects and to manage the increasingly higher investments made in this area. In 2022, the R&D area received investments amounting to R$ 615 million, equivalent to 6,7% of the company’s net revenue, a 4% higher figure if compared to the previous year. Currently, our development pipeline includes more than 400 products.  

Biochemists, chemists and pharmacists reinforce our teams in the pre-clinical development area. Such an expansion has also generated many growth opportunities to those collaborators who had already been working in this area. Altogether, 627 collaborators are dedicated to the development of new products.  

One of the focal points of our Research and Development projects is to serve those segments still unattended by the pharmaceutical industry, such as the antibiotics, metabolism and obesity, central nervous system, and oncology divisions. In the radical innovation area, our effort has been directed to developing some anti-infectious molecules that face unattended demands in the Southern hemisphere. That is why Eurofarma has been a member of the international Research and Development front for neglected diseases. 

The result of our investments can be demonstrated by the exponential growth of the main indicators in the area, such as an 82% increase in the number of products in our pipeline, an 18% evolution in the number of stabilized products, and the number of dossiers submitted to the National Health Surveillance Agency (Anvisa), which increased by 110% if compared to year 2021.  

For the second consecutive year, Eurofarma has kept its leadership position in terms of market share of new products launched in the last 24 months. In 2022, it amounted to 188 products, with 45 in Brazil and 143 in other Latin American countries. The highlight goes to innovative products Delabaxi®, Suganon®, and Nuvyor® launched in Brazil.  

Another fundamental achievement has been the certification granted by the FDA (U.S. Food and Drug Administration), the North American health surveillance agency, to the industrial plant of the Unit of Itapevi, which has reinforced our commitment to quality products and processes.